HOME >> BIOLOGY >> NEWS
Cellular dumping site is not garbage after all

Cells can reuse the chemical messengers that carry genetic information to the machinery that makes proteins. Sometimes cells shuttle the messengers to storage and later reactivate them to make proteins, according to new research.

Learning how cells regulate the newly discovered "mRNA cycle" may provide insights into how the cellular machinery runs amok in diseases like cancer.

Scientists had previously thought the messenger molecules, known as mRNAs, were manufactured, used, decommissioned and then sent on a one-way journey to the garbage dump.

These cellular garbage dumps, called P-bodies, turn out to be storage depots, not landfills. After use, mRNA molecules are temporarily deactivated for storage purposes. The cell can then either destroy the mRNA or recondition pre-used mRNA so it can be put back into service if needed.

P-bodies are also involved in determining whether specific mRNAs are used to make proteins, a process called translation.

"We were surprised to find that the P-bodies were involved in regulating translation," said research team leader Roy Parker, a Regents' Professor of molecular and cellular biology at The University of Arizona in Tucson and an Investigator with the Howard Hughes Medical Institute. In 2003, his lab was the first to name and describe a function for P-bodies.

Parker said of the new finding, "It suggests P-bodies have a much broader role in controlling the activities of the cell than we realized."

Parker and first author Jeff Coller report P-bodies' role in the control of translation in the Sept. 23 issue of the journal Cell. Coller, who did the research while at UA as a postdoctoral fellow with the Howard Hughes Medical Institute, is now an assistant professor in the Center for RNA Molecular Biology at Case Western Reserve University in Cleveland, Ohio.

The Parker lab's findings about P-bodies serving as storage depots was released online Sept. 1, 2005 and will be pu
'"/>

Contact: Mari N. Jensen
mnjensen@email.arizona.edu
520-626-9635
University of Arizona
22-Sep-2005


Page: 1 2 3

Related biology news :

1. Story ideas from Molecular & Cellular Proteomics
2. Cellular message movement captured on video
3. Cellular pathway yields potential new weapon in vaccine arsenal
4. Cellular cues identified for stroke recovery
5. Cellular killer also important to memory
6. Cellular traffic backups implicated in skeletal malformations
7. Cellular antennae on algae give clues to how human cells receive signals
8. Cellular scale drug delivery from the inside out
9. Cellular power plants also fend off viruses
10. World Wildlife Fund warns against iron dumping experiment near the Galapagos Islands
11. MIT warns of dumping seafood

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cellular dumping site not garbage after all

(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: